TP53 and acute myeloid leukemia: However, unlike the oncogenic clone of cells carrying both SF3B1 and TP53 mutations, this putative pathogenic clone of cells did not expand much during AML progression (~5% VAF at all time-points), (Fig. 1B, 1D), indicating that this particular clone was not associated with AML relapse.